Hai-Feng Zhou

Hai-Feng Zhou

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
HZHai-Feng Zhou
Hai-Feng Zhou
MHMing Huang
Ming Huang
JJJian-Song Ji
Jian-Song Ji
HZHai-Dong Zhu
Hai-Dong Zhu
JLJian Lu
Jian Lu
GTGao-Jun Teng
Gao-Jun Teng

28 July 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
WDWei Ding
Wei Ding
JZJinxing Zhang
Jinxing Zhang
ZJZhicheng Jin
Zhicheng Jin
HHHongjin Hua
Hongjin Hua
QZQing-Quan Zu
Qing-Quan Zu
HSHaibin Shi
Haibin Shi
Hepatocellular carcinoma (HCC) is a highly malignant tumor with elevated incidence and mortality rates globally. Its complex etiology and pronounced heterogeneity present significant challenges in diagnosis and treatment. Recent advancements in artificial intelligence (AI) have demonstrated transformative potential to usher a new wave of precision oncology. Pathomics, an AI-based digital pathology technique, facilitates the extraction of extensive datasets from whole-slide histopathological images, enabling quantitative analyses to improve diagnosis, treatment, and prognostic prediction for HCC. Furthermore, emerging pathological foundation models are revolutionizing traditional paradigms and providing a robust framework for the development of specialized pathomics models tailored to specific clinical tasks in HCC. Despite its promise, pathomics research in HCC remains in its infancy, with clinical implementation hindered by challenges such as data heterogeneity, model interpretability, ethical concerns, regulatory issues, and the absence of standardized industry protocols. Future initiatives should prioritize the conduction of prospective multi-center studies, the integration of multi-modal data, the enhancement of regulatory frameworks, and the establishment of industry-wide standardized guidelines and compliant platform infrastructures to accelerate the clinical adoption of pathomics for personalized HCC treatment.

19 January 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
HZHai-Feng Zhou
Hai-Feng Zhou
WYWei Yang
Wei Yang
WZWei-Zhong Zhou
Wei-Zhong Zhou

17 September 2024 in Digestive and Liver Disease
Verified
Journal Article
Open access
BWBifei Wu
Bifei Wu
WYWei Yang
Wei Yang
YXYuguan Xie
Yuguan Xie
HZHai-Feng Zhou
Hai-Feng Zhou
HSHaibin Shi
Haibin Shi
WZWeizhong Zhou
Weizhong Zhou
Non-cirrhotic porto-mesenteric vein thrombosis (NC-PMVT) is a rare but severe clinical condition. The study aims to assess the effectiveness and safety of transjugular intrahepatic portosystemic shunt (TIPS) coupled with dual-access thrombolysis in patients with acute severe NC-PMVT. From January 2018 to February 2023, a total of 25 patients with acute severe NC-PMVT who were treated with TIPS in conjunction with mechanical thrombectomy and dual-access thrombolysis. The period of thrombolysis was determined by the improvement of clinical symptoms and vascular recanalization. The technical success, recanalization rate, clinical success, and procedure-related complications were analyzed. The technical success rate was 100 %. The median duration for thrombolytic catheter removal was 5 (IQR 3.5 - 7) days. Full and partial recanalization were accomplished in 10 (40 %) and 15 (60 %) patients respectively before discharge. No significant procedure-related complications were reported. The clinical success rate was 88 %, with a mortality rate of 12 %. Over a median follow-up of 8 months, 3/22 (13.64 %) patients had a recurrence of thrombosis; 1/22 (4.54 %) patients underwent partial intestinal resection one and a half months post-discharge; the remaining patients did not experience any portal hypertensive complications. The combination of TIPS and dual-access thrombolysis appears to be safe and effective for patients with acute severe NC-PMVT.

1 January 2025 in Translational Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
BYBing-Jie Yang
Bing-Jie Yang
HZHai-Feng Zhou
Hai-Feng Zhou
YLYu Liu
Yu Liu
WYWei Yang
Wei Yang
LJLi Jia
Li Jia
WZWei-Zhong Zhou
Wei-Zhong Zhou
Background and Objective: Ultrasound (US)-targeted microbubble (MB) destruction (UTMD) involves the application of low-intensity US to MBs. This review is to illustrate the current progress and futural prospects of UTMD for liver diseases. Methods: A review of the most recent literature concerning the use of UTMD for liver diseases is presented from January 2000 to December 2023. A comprehensive search was conducted by two independent reviewers. In this review, we provide an overview of various preclinical applications of UTMD in the delivery of drugs and genes to target liver diseases, including liver cancer, liver fibrosis, and hepatic gene deficiency disorders, which have established the safety and effectiveness. Key Content and Findings: A total of 9 studies and 14 studies were identified about the preclinical applications for drug-loaded and gene-loaded UTMD for liver diseases, respectively. UTMD allows specific substances to bypass physiological barriers and reach target tissues or organs. It has been demonstrated to enhance hepatic disease drug delivery. UTMD still requires improvement in many areas, including sonographic parameters, drug-loading capacity, and range of treatable diseases. Conclusions: UTMD was shown in preclinical studies to enhance the therapeutic efficacy of drug delivery and gene therapy for liver cancer, liver fibrosis and hepatic gene defect diseases. Further clinical trials are emergent to evaluate the safety, effectiveness and long-term efficacy of UTMD in treating human liver diseases.

30 September 2026 in Academic Radiology
Verified
Journal Article
Closed access
YHYun-Xuan He
Yun-Xuan He
HDHao-Cheng Dai
Hao-Cheng Dai
SPShu-Tong Pan
Shu-Tong Pan
YZYu-Zhou Zhang
Yu-Zhou Zhang
YTYuan-Ze Tang
Yuan-Ze Tang
HZHai-Feng Zhou
Hai-Feng Zhou